Patrick Harrison Carroll Sells 23,287 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Patrick Harrison Carroll sold 23,287 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total value of $798,976.97. Following the completion of the sale, the insider now owns 209,661 shares in the company, valued at $7,193,468.91. The trade was a 10.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Hims & Hers Health Stock Up 7.5 %

NYSE HIMS opened at $33.85 on Thursday. The company has a 50-day moving average price of $38.88 and a 200-day moving average price of $28.52. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The firm has a market capitalization of $7.52 billion, a P/E ratio of 76.94 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analysts Forecast Growth

HIMS has been the topic of a number of recent research reports. Leerink Partners increased their target price on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 25th. Citigroup reissued a “sell” rating and set a $27.00 price objective on shares of Hims & Hers Health in a research report on Thursday, March 6th. BTIG Research assumed coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price on the stock. Truist Financial raised their price target on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a research report on Wednesday, February 26th. Finally, Bank of America upped their price objective on Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $37.31.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently bought and sold shares of HIMS. Crewe Advisors LLC purchased a new position in shares of Hims & Hers Health during the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. raised its stake in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 1,100 shares during the period. Blume Capital Management Inc. lifted its holdings in Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 600 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC bought a new position in shares of Hims & Hers Health in the fourth quarter worth approximately $38,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.